Featured Articles

Moderna, Inc. and Laboratorios Farmacéuticos Rovi, S.A. announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA vaccine candidate against…
Read More...

Pfizer Inc. announced it has pledged $100 million to the new Antimicrobial Resistance (AMR) Action Fund, which launched today, to help address the significant global public health need…
Read More...

Boehringer Ingelheim and Numab Therapeutics (Numab) announced that they have entered into a research collaboration and worldwide licensing agreement. It will start with two projects…
Read More...

GSK and Medicago announced a collaboration to develop and evaluate a COVID-19 candidate vaccine combining Medicago’s recombinant Coronavirus Virus-Like Particles (CoVLP) with GSK’s…
Read More...

Sarepta Therapeutics, Inc. announced an agreement with Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare Immunoglobulin G (IgG) mediated diseases, for…
Read More...

Symbiosis Pharmaceutical Services, a specialist provider of pharmaceutical and vaccine development services, has announced it has signed a supply agreement with AstraZeneca for sterile…
Read More...

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, have agreed to expand their existing 2018…
Read More...

Gilead Sciences, Inc. announced that for $275 million the company will acquire a 49.9 percent equity interest in Pionyr Immunotherapeutics Inc., a privately held company developing…
Read More...

Neurocrine Biosciences, Inc. and Takeda Pharmaceutical Company Limited announced a strategic collaboration to develop and commercialize compounds in Takeda’s early-to-mid-stage…
Read More...

Jazz Pharmaceuticals plc announced along with its partner PharmaMar that the U.S. Food and Drug Administration (FDA) approved Zepzelca (lurbinectedin) for the treatment of adult…
Read More...

The U.S. Food and Drug Administration approved Tivicay (dolutegravir) tablets and Tivicay PD (dolutegravir) tablets for suspension to treat HIV-1 infection in pediatric patients at…
Read More...

Daiichi Sankyo Company, Limited announced its decision to develop a genetic (mRNA) vaccine for the novel corona virus infection (hereinafter, COVID-19) in Japan. In April, 2020,…
Read More...

Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced the sale of its portfolio company Corvidia Therapeutics to Novo…
Read More...

Grifols announced the start of production of its anti-SARS-CoV-2 hyperimmune immunoglobulin with specific antibodies using the plasma of people who have overcome the disease. It is the…
Read More...

The European Commission (EC) has approved Sarclisa (isatuximab) in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of adult patients with relapsed and…
Read More...

AbbVie and Jacobio Pharmaceuticals announced a global, strategic collaboration to develop and commercialize SHP2 inhibitors, which target a key node in cancer and immune cells. SHP2 …
Read More...

Roche announced the initiation of a global phase III, randomised, double-blind, multicentre study (REMDACTA) to evaluate the safety and efficacy of Actemra/RoActemra plus the…
Read More...

Almac Group has received a $288,000 grant to support a clinical study in Sub-Saharan Africa in efforts to find a treatment for Coronavirus. This was awarded from the COVID-19…
Read More...

GlaxoSmithKline plc (GSK) announced that the US Food and Drug Administration (FDA) has granted a priority review for the company’s application seeking approval of Nucala (mepolizumab)…
Read More...

Boehringer Ingelheim announced the acquisition of Northern Biologics Inc., a wholly owned subsidiary of Northern LP. By acquiring this entity, which focuses on therapeutic antibodies…
Read More...